Trials / Completed
CompletedNCT02442284
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 99 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in US veterans with genotype 1 chronic hepatitis C virus infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ombitasvir/paritaprevir/ritonavir and dasabuvir | Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet |
| DRUG | Ribavirin | Tablet |
Timeline
- Start date
- 2015-05-13
- Primary completion
- 2016-08-22
- Completion
- 2016-10-31
- First posted
- 2015-05-13
- Last updated
- 2017-10-16
- Results posted
- 2017-08-30
Source: ClinicalTrials.gov record NCT02442284. Inclusion in this directory is not an endorsement.